UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________
FORM
___________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
___________________________________________
(Exact name of registrant as specified in its charter)
___________________________________________
|
|
|
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive office) (zip code)
Registrant's telephone number, including area code: (
_________________________________________________________
(Former name or former address, if changed since last report)
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange |
___________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Section 2Financial Information
Item 2.02Results of Operations and Financial Condition
On November 4, 2021, CryoLife, Inc. (“CryoLife” or the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. CryoLife hereby incorporates by reference herein the information set forth in its press release dated November 4, 2021, a copy of which is attached hereto as Exhibit 99.1. Except as otherwise provided in the press release, the press release speaks only as of the date of such press release and it shall not create any implication that the affairs of CryoLife have continued unchanged since such date.
The information provided pursuant to this Item 2.02 is to be considered “furnished” pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any of CryoLife’s reports or filings with the Securities and Exchange Commission, whether made before or after the date hereof, except as expressly set forth by specific reference in such report or filing.
Except for the historical information contained in this report, the statements made by CryoLife are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. CryoLife’s future financial performance could differ significantly from the expectations of management and from results expressed or implied in the press release. Please refer to the last paragraph of the text portion of the press release for further discussion about forward-looking statements. For further information on risk factors, please refer to “Risk Factors” contained in CryoLife’s most recently filed Form 10-K and its subsequent filings with the Securities and Exchange Commission, as well as in the press release attached as Exhibit 99.1 hereto. CryoLife disclaims any obligation or duty to update or modify these forward-looking statements.
|
|
Section 9 | Financial Statements and Exhibits. |
|
|
Item 9.01(d) | Exhibits |
|
|
(d) | Exhibits. |
|
|
Exhibit Number | Description |
99.1* | Press Release dated November 4, 2021 |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
|
* Furnished herewith, not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 4, 2021
|
|
|
| CRYOLIFE, INC. | |
|
|
|
| By: | /s/ D. Ashley Lee |
| Name: | D. Ashley Lee |
| Title: | Executive Vice President, Chief Operating Officer and Chief Financial Officer |
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contacts:
|
CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 |
Gilmartin Group LLC Brian Johnston / Lynn Lewis Phone: 631-807-1986 investors@cryolife.com |
CryoLife Reports Third Quarter 2021 Financial Results
Third Quarter and Recent Business Highlights:
|
· |
Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis |
|
· |
Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 |
|
· |
Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021 |
ATLANTA, GA – (November 4, 2021) – CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the third quarter ended September 30, 2021.
“Despite meaningful headwinds from the Delta variant in the third quarter, we still generated revenue growth on both a GAAP and pro forma constant currency basis compared to the prior year and compared to 2019, driven by our recent product launches and strength in our U.S. On-X aortic valve business. We’ve also made progress in driving growth across APAC and LATAM as we continue to expand our commercial footprint and seek new regulatory approvals,” said Pat Mackin, Chairman, President, and Chief Executive Officer.
“Additionally, we have submitted PMAs to FDA for PerClot and PROACT Mitral and anticipate receiving approvals for both in 2022. We’ve also made significant progress with enrollment in our PROACT Xa clinical trial and continue to advance several other programs which are expected to deliver incremental growth beginning in 2024.”
“Given our solid financial foundation, performance of our new products, market expansion opportunities and a strong pipeline, CryoLife is very well positioned now and for the future.”
Third Quarter 2021 Financial Results
Total revenues for the third quarter of 2021 were $72.2 million, reflecting an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis, both compared to the third quarter of 2020.
Page 1 of 9
Net income for the third quarter of 2021 was $10.6 million, or $0.26 per fully diluted common share, compared to net loss of ($2.9) million, or ($0.08) per fully diluted common share for the third quarter of 2020. Non-GAAP net loss for the third quarter of 2021 was ($1.2) million, or ($0.03) per fully diluted common share, compared to non-GAAP net income of $4.9 million, or $0.13 per fully diluted common share for the third quarter of 2020.
The financial results reported in this earnings release are preliminary pending the Company’s filing of its quarterly report on Form 10-Q, which it expects to file on November 5, 2021.
2021 Financial Outlook
The Company is maintaining its second half of 2021 proforma constant currency growth outlook of between 7 and 10% compared to the second half of 2019, but due to the strengthening dollar, revenues for the full year are expected to be between $296.0 and $299.0 million dollars and fourth quarter revenues are expected to be between $76.5 and $79.5 million dollars, reflecting pro forma constant currency growth of between 9.5% and 13.7% over the fourth quarter of 2019. This forecast is based on our estimates of the current and an anticipated diminishing impact of COVID-19 on our business.
The Company's financial performance for the remainder of 2021 and future periods is subject to the risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including non-GAAP revenue, non-GAAP net income, non-GAAP EBITDA, and non-GAAP adjusted operating income. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with U.S. GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP revenues are adjusted for revenues of acquired and divested product lines and the impact of changes in currency exchange. The Company’s non-GAAP net income, non-GAAP EBITDA, and non-GAAP adjusted operating income results exclude (as applicable) business development, integration, and severance expense; gain from sale of non-financial assets; depreciation and amortization expense; interest income and expense; non-cash interest expense; loss (gain) on foreign currency revaluation; stock-based compensation expense; corporate rebranding expense; and income tax expense (benefit). The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions; the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses and the transaction and integration expenses incurred in connection with recently acquired and divested product lines; and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as acquisitions, or non-cash expense related to amortization of previously acquired tangible and intangible assets. The Company has adjusted for the impact of acquired and divested product lines and changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety.
Page 2 of 9
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast later today, November 4, 2021 at 4:30 p.m. ET to discuss the results followed by a question and answer session. To participate in the conference call dial 862-298-0702. An audio replay will be available through November 11, 2021 and can be accessed by dialing (toll free) 877-660-6853 or 201-612-7415. The Conference ID for the replay is 13724263.
The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations.
About CryoLife, Inc.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide. For additional information about CryoLife, visit our website, www.cryolife.com.
Forward Looking Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date of this press release and reflect the view of management as of the date of this press release. Forward-looking statements include statements related to future regulatory approvals, the progress and future results of clinical trials, future product launches, commercial footprint expansion, market performance of our current and future products, revenue and earnings growth related to current and newly introduced products, our forecasted revenue and earnings, and the effects of the COVID-19 pandemic on our business. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations, including that the benefits anticipated from the Ascyrus Medical LLC transaction and Endospan distribution agreement may not be achieved, that the benefits anticipated from our clinical trials may not be achieved or achieved on our anticipated timelines, that our product candidates may not receive regulatory approval or receive regulatory approval on our anticipated timelines, that our products that obtain regulatory approval may not be accepted by the market, and the continued effects of COVID-19, including decelerating vaccination or vaccine adoption rates, or government mandates implemented to address the effects of the pandemic, could adversely impact our results. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for year ended December 31, 2020. CryoLife does not assume any obligation, and expressly disclaims any duty to update any of its forward-looking statements, whether as a result of new information, future events, or otherwise.
Page 3 of 9
CryoLife, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss)
(In thousands, except per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
September 30, |
|
September 30, |
||||||||
|
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
Products |
$ |
53,107 |
|
$ |
45,109 |
|
$ |
162,528 |
|
$ |
128,797 |
|
Preservation services |
|
19,100 |
|
|
20,022 |
|
|
56,914 |
|
|
56,534 |
|
Total revenues |
|
72,207 |
|
|
65,131 |
|
|
219,442 |
|
|
185,331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of products and preservation services: |
|
|
|
|
|
|
|
|
|
|
|
|
Products |
|
15,503 |
|
|
12,998 |
|
|
46,592 |
|
|
36,078 |
|
Preservation services |
|
8,915 |
|
|
9,001 |
|
|
26,710 |
|
|
26,060 |
|
Total cost of products and preservation services |
|
24,418 |
|
|
21,999 |
|
|
73,302 |
|
|
62,138 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
|
47,789 |
|
|
43,132 |
|
|
146,140 |
|
|
123,193 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
General, administrative, and marketing |
|
39,053 |
|
|
33,743 |
|
|
118,521 |
|
|
105,033 |
|
Research and development |
|
9,972 |
|
|
5,755 |
|
|
26,086 |
|
|
17,633 |
|
Total operating expenses |
|
49,025 |
|
|
39,498 |
|
|
144,607 |
|
|
122,666 |
|
Gain from sale of non-financial assets |
|
(15,923) |
|
|
-- |
|
|
(15,923) |
|
|
-- |
|
Operating income |
|
14,687 |
|
|
3,634 |
|
|
17,456 |
|
|
527 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
4,100 |
|
|
4,940 |
|
|
12,995 |
|
|
11,980 |
|
Interest income |
|
(18) |
|
|
(13) |
|
|
(60) |
|
|
(181) |
|
Other expense, net |
|
2,661 |
|
|
2,888 |
|
|
3,261 |
|
|
5,810 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
|
7,944 |
|
|
(4,181) |
|
|
1,260 |
|
|
(17,082) |
|
Income tax benefit |
|
(2,638) |
|
|
(1,311) |
|
|
(4,006) |
|
|
(3,858) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
$ |
10,582 |
|
$ |
(2,870) |
|
$ |
5,266 |
|
$ |
(13,224) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
$ |
0.27 |
|
|
(0.08) |
|
$ |
0.13 |
|
|
(0.35) |
|
Diluted |
$ |
0.26 |
|
$ |
(0.08) |
|
$ |
0.13 |
|
$ |
(0.35) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
39,086 |
|
|
37,912 |
|
|
38,924 |
|
|
37,608 |
|
Diluted |
|
44,453 |
|
|
37,912 |
|
|
39,496 |
|
|
37,608 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
$ |
10,582 |
|
$ |
(2,870) |
|
$ |
5,266 |
|
$ |
(13,224) |
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
|
(5,010) |
|
|
8,698 |
|
|
(12,327) |
|
|
8,669 |
|
Comprehensive income (loss) |
$ |
5,572 |
|
$ |
5,828 |
|
$ |
(7,061) |
|
$ |
(4,555) |
Page 4 of 9
CryoLife, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands)
|
|
September 30, |
December 31, |
|||
|
|
2021 |
2020 |
|||
|
|
(Unaudited) |
||||
|
ASSETS |
|||||
|
Current assets: |
|||||
|
Cash and cash equivalents |
$ |
64,587 |
$ |
61,412 | |
|
Restricted securities |
538 | 546 | |||
|
Trade receivables, net |
49,682 | 45,964 | |||
|
Other receivables |
5,494 | 2,788 | |||
|
Inventories, net |
78,319 | 73,038 | |||
|
Deferred preservation costs |
42,619 | 36,546 | |||
|
Prepaid expenses and other |
16,104 | 14,295 | |||
|
Total current assets |
257,343 | 234,589 | |||
|
|
|||||
|
Goodwill |
252,441 | 260,061 | |||
|
Acquired technology, net |
171,788 | 186,091 | |||
|
Operating lease right-of-use assets, net |
46,913 | 18,571 | |||
|
Other intangibles, net |
36,001 | 40,966 | |||
|
Property and equipment, net |
36,973 | 33,077 | |||
|
Deferred income taxes |
3,974 | 1,446 | |||
|
Other assets |
13,221 | 14,603 | |||
|
Total assets |
$ |
818,654 |
$ |
789,404 | |
|
|
|||||
|
LIABILITIES AND SHAREHOLDERS' EQUITY |
|||||
|
Current liabilities: |
|||||
|
Current portion of contingent consideration |
$ |
17,600 |
$ |
16,430 | |
|
Accounts payable |
9,528 | 9,623 | |||
|
Accrued compensation |
11,990 | 10,192 | |||
|
Accrued expenses |
9,091 | 7,472 | |||
|
Accrued procurement fees |
3,296 | 3,619 | |||
|
Taxes payable |
3,129 | 2,808 | |||
|
Current maturities of operating leases |
3,053 | 5,763 | |||
|
Current portion of long-term debt |
1,640 | 1,195 | |||
|
Other liabilities |
1,803 | 3,366 | |||
|
Total current liabilities |
61,130 | 60,468 | |||
|
|
|||||
|
Long-term debt |
307,765 | 290,468 | |||
|
Non-current maturities of operating leases |
45,765 | 14,034 | |||
|
Contingent consideration |
47,300 | 43,500 | |||
|
Deferred income taxes |
27,339 | 34,713 | |||
|
Deferred compensation liability |
5,571 | 5,518 | |||
|
Other liabilities |
12,243 | 11,990 | |||
|
Total liabilities |
$ |
507,113 |
$ |
460,691 | |
|
|
|||||
|
Commitments and contingencies |
|||||
|
|
|||||
|
Shareholders' equity: |
|||||
|
Preferred stock |
-- |
-- |
|||
|
Common stock (issued shares of 40,816 in 2021 and 40,394 in 2020) |
408 | 404 | |||
|
Additional paid-in capital |
309,290 | 316,192 | |||
|
Retained earnings |
22,075 | 20,022 | |||
|
Accumulated other comprehensive (loss) income |
(5,584) | 6,743 | |||
|
Treasury stock, at cost, 1,487 shares as of September 30, 2021 |
(14,648) | (14,648) | |||
|
Total shareholders' equity |
311,541 | 328,713 | |||
|
|
|||||
|
Total liabilities and shareholders' equity |
$ |
818,654 |
$ |
789,404 | |
Page 5 of 9
CryoLife, Inc. and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(In thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
Nine Months Ended |
||||
|
|
September 30, |
||||
|
|
|
2021 |
|
|
2020 |
|
Net cash flows from operating activities: |
|
|
|
|
|
|
Net income (loss) |
$ |
5,266 |
|
$ |
(13,224) |
|
|
|
|
|
|
|
|
Adjustments to reconcile net income (loss) to net cash from operating activities: |
|
|
|
|
|
|
Depreciation and amortization |
|
18,008 |
|
|
14,818 |
|
Non-cash compensation |
|
7,471 |
|
|
7,432 |
|
Non-cash lease expense |
|
5,566 |
|
|
5,324 |
|
Change in fair value of contingent consideration |
|
4,970 |
|
|
-- |
|
Non-cash interest expense |
|
2,025 |
|
|
2,261 |
|
Change in fair value of long-term loan |
|
-- |
|
|
4,949 |
|
Deferred income taxes |
|
(8,128) |
|
|
(4,916) |
|
Gain from sale of non-financial assets |
|
(15,923) |
|
|
-- |
|
Other |
|
4,665 |
|
|
1,631 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
Accounts payable, accrued expenses, and other liabilities |
|
65 |
|
|
3,230 |
|
Prepaid expenses and other assets |
|
(2,268) |
|
|
(2,560) |
|
Receivables |
|
(8,032) |
|
|
7,718 |
|
Inventories and deferred preservation costs |
|
(16,986) |
|
|
(19,744) |
|
Net cash flows (used in) provided by operating activities |
|
(3,301) |
|
|
6,919 |
|
|
|
|
|
|
|
|
Net cash flows from investing activities: |
|
|
|
|
|
|
Proceeds from sale of non-financial assets, net |
|
19,000 |
|
|
-- |
|
Acquisition of Ascyrus, net of cash acquisition |
|
-- |
|
|
(59,643) |
|
Payments for Endospan agreements |
|
-- |
|
|
(5,000) |
|
Capital expenditures |
|
(10,524) |
|
|
(5,171) |
|
Other |
|
(4) |
|
|
(968) |
|
Net cash flows provided by (used in) investing activities |
|
8,472 |
|
|
(70,782) |
|
|
|
|
|
|
|
|
Net cash flows from financing activities: |
|
|
|
|
|
|
Proceeds from exercise of stock options and issuance of common stock |
|
3,531 |
|
|
2,079 |
|
Proceeds from issuance of convertible debt |
|
-- |
|
|
100,000 |
|
Proceeds from revolving line of credit |
|
-- |
|
|
30,000 |
|
Proceeds from financing insurance premiums |
|
-- |
|
|
2,816 |
|
Repayment of revolving line of credit |
|
-- |
|
|
(30,000) |
|
Redemption and repurchase of stock to cover tax withholdings |
|
(1,898) |
|
|
(1,768) |
|
Payment of debt issuance costs |
|
(2,219) |
|
|
(3,647) |
|
Repayment of debt |
|
(2,397) |
|
|
(3,727) |
|
Other |
|
(439) |
|
|
(463) |
|
Net cash flows (used in) provided by financing activities |
|
(3,422) |
|
|
95,290 |
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash, cash equivalents, and restricted securities |
|
1,418 |
|
|
(1,086) |
|
Increase in cash, cash equivalents, and restricted securities |
|
3,167 |
|
|
30,341 |
|
|
|
|
|
|
|
|
Cash, cash equivalents, and restricted securities beginning of period |
|
61,958 |
|
|
34,294 |
|
Cash, cash equivalents, and restricted securities end of period |
$ |
65,125 |
|
$ |
64,635 |
Page 6 of 9
CryoLife, Inc. and Subsidiaries
Financial Highlights
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited) |
|
(Unaudited) |
||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||
|
|
September 30, |
|
September 30, |
||||||||
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||
|
Products: |
|
|
|
|
|
|
|
|
|
|
|
|
Aortic stents and stent grafts |
$ |
20,896 |
|
$ |
15,290 |
|
$ |
62,165 |
|
$ |
43,932 |
|
Surgical sealants |
|
16,544 |
|
|
15,811 |
|
|
52,236 |
|
|
44,985 |
|
On-X |
|
14,022 |
|
|
12,067 |
|
|
41,843 |
|
|
34,385 |
|
Other |
|
1,645 |
|
|
1,941 |
|
|
6,284 |
|
|
5,495 |
|
Total products |
|
53,107 |
|
|
45,109 |
|
|
162,528 |
|
|
128,797 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preservation services |
|
19,100 |
|
|
20,022 |
|
|
56,914 |
|
|
56,534 |
|
Total revenues |
$ |
72,207 |
|
$ |
65,131 |
|
$ |
219,442 |
|
$ |
185,331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues: |
|
|
|
|
|
|
|
||||
|
U.S. |
$ |
36,205 |
|
$ |
36,332 |
|
$ |
111,529 |
|
$ |
103,171 |
|
International |
|
36,002 |
|
|
28,799 |
|
|
107,913 |
|
|
82,160 |
|
Total revenues |
$ |
72,207 |
|
$ |
65,131 |
|
$ |
219,442 |
|
$ |
185,331 |
Page 7 of 9
CryoLife, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
Revenues and Adjusted EBITDA
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
(Unaudited) |
|
(Unaudited) |
||||||||||||||||||
|
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||||||||
|
|
September 30, |
|
September 30, |
||||||||||||||||||
|
|
2021 |
|
2020 |
Growth Rate |
|
2021 |
|
2020 |
Growth Rate |
||||||||||||
|
Reconciliation of total revenues, GAAP to |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
total revenues, non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Total revenues, GAAP |
$ |
72,207 |
|
$ |
65,131 |
11% |
|
$ |
219,442 |
|
$ |
185,331 |
18% |
||||||||
|
Including AMDS prior to acquisition |
|
-- |
|
|
691 |
|
|
|
-- |
|
|
2,088 |
|
||||||||
|
Excluding PerClot post sale |
|
-- |
|
|
(498) |
|
|
|
-- |
|
|
(498) |
|
||||||||
|
Impact of changes in currency exchange |
|
-- |
|
|
824 |
|
|
|
-- |
|
|
4,358 |
|
||||||||
|
Total proforma constant currency revenue, non-GAAP |
$ |
72,207 |
|
$ |
66,148 |
9% |
|
$ |
219,442 |
|
$ |
191,279 |
15% |
||||||||
|
|
(Unaudited) |
(Unaudited) |
||||||||||
|
|
Three Months Ended |
Nine Months Ended |
||||||||||
|
|
September 30, |
September 30, |
||||||||||
|
|
2021 |
2020 |
2021 |
2020 |
||||||||
|
Reconciliation of operating income, GAAP to |
||||||||||||
|
adjusted operating income, non-GAAP: |
||||||||||||
|
Operating income |
$ |
14,687 |
$ |
3,634 |
$ |
17,456 |
$ |
527 | ||||
|
Gain from sale of non-financial assets |
(15,923) |
-- |
(15,923) |
-- |
||||||||
|
Amortization expense |
4,203 | 3,397 | 12,701 | 9,430 | ||||||||
|
Operating business development, integration, and severance expense |
1,309 | 1,056 | 6,138 | 2,532 | ||||||||
|
Corporate rebranding expense |
461 |
-- |
523 | 321 | ||||||||
|
Adjusted operating income, non-GAAP |
$ |
4,737 |
$ |
8,087 |
$ |
20,895 |
$ |
12,810 | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited) |
|
|
(Unaudited) |
||||||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
||||||||
|
|
September 30, |
|
|
September 30, |
||||||||
|
|
2021 |
|
2020 |
|
|
2021 |
|
2020 |
||||
|
Reconciliation of net income (loss), GAAP to |
|
|
|
|
|
|
|
|
|
|
|
|
|
adjusted EBITDA, non-GAAP: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss), GAAP |
$ |
10,582 |
|
$ |
(2,870) |
|
|
$ |
5,266 |
|
$ |
(13,224) |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization expense |
|
6,009 |
|
|
5,176 |
|
|
|
18,008 |
|
|
14,818 |
|
Interest expense |
|
4,100 |
|
|
4,940 |
|
|
|
12,995 |
|
|
11,980 |
|
Stock-based compensation expense |
|
2,876 |
|
|
2,358 |
|
|
|
7,471 |
|
|
7,432 |
|
Business development, integration, and severance expense |
|
1,309 |
|
|
6,005 |
|
|
|
6,138 |
|
|
7,481 |
|
Loss (gain) on foreign currency revaluation |
|
2,576 |
|
|
(2,073) |
|
|
|
3,097 |
|
|
846 |
|
Corporate rebranding expense |
|
461 |
|
|
-- |
|
|
|
523 |
|
|
321 |
|
Interest income |
|
(18) |
|
|
(13) |
|
|
|
(60) |
|
|
(181) |
|
Income tax benefit |
|
(2,638) |
|
|
(1,311) |
|
|
|
(4,006) |
|
|
(3,858) |
|
Gain from sale of non-financial assets |
|
(15,923) |
|
|
-- |
|
|
|
(15,923) |
|
|
-- |
|
Adjusted EBITDA, non-GAAP |
$ |
9,334 |
|
$ |
12,212 |
|
|
$ |
33,509 |
|
$ |
25,615 |
Page 8 of 9
CryoLife, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
Net Income (Loss) and Diluted Income (Loss) Per Common Share
(In thousands, except per share data)
|
|
(Unaudited) |
(Unaudited) |
|||||||||
|
|
Three Months Ended |
Nine Months Ended |
|||||||||
|
|
September 30, |
September 30, |
|||||||||
|
|
2021 |
2020 |
2021 |
2020 |
|||||||
|
GAAP: |
|||||||||||
|
Income (loss) before income taxes |
$ |
7,944 |
$ |
(4,181) |
$ |
1,260 |
$ |
(17,082) | |||
|
Income tax benefit |
(2,638) | (1,311) | (4,006) | (3,858) | |||||||
|
Net income (loss) |
$ |
10,582 |
$ |
(2,870) |
$ |
5,266 |
$ |
(13,224) | |||
|
|
|||||||||||
|
Diluted income (loss) per common share: |
$ |
0.26 |
$ |
(0.08) |
$ |
0.13 |
$ |
(0.35) | |||
|
|
|||||||||||
|
Diluted weighted-average common shares outstanding |
44,453 | 37,912 | 39,496 | 37,608 | |||||||
|
|
|||||||||||
|
Reconciliation of income (loss) before income taxes, |
|||||||||||
|
GAAP to adjusted (loss) income, non-GAAP |
|||||||||||
|
Income (loss) before income taxes, GAAP: |
$ |
7,944 |
$ |
(4,181) |
$ |
1,260 |
$ |
(17,082) | |||
|
Adjustments: |
|||||||||||
|
Amortization expense |
4,203 | 3,397 | 12,701 | 9,430 | |||||||
|
Gain from sale of non-financial assets |
(15,923) |
-- |
(15,923) |
-- |
|||||||
|
Business development, integration, and severance expense |
1,309 | 6,005 | 6,138 | 7,481 | |||||||
|
Non-cash interest expense |
453 | 1,371 | 2,025 | 2,261 | |||||||
|
Corporate rebranding expense |
461 |
-- |
523 | 321 | |||||||
|
Adjusted (loss) income before income taxes, |
|||||||||||
|
non-GAAP |
(1,553) | 6,592 | 6,724 | 2,411 | |||||||
|
|
|||||||||||
|
Income tax (benefit) expense calculated at a |
|||||||||||
|
pro forma tax rate of 25% |
(388) | 1,648 | 1,681 | 603 | |||||||
|
Adjusted net (loss) income, non-GAAP |
$ |
(1,165) |
$ |
4,944 |
$ |
5,043 |
$ |
1,808 | |||
|
|
|||||||||||
|
Reconciliation of diluted income (loss) per common share, GAAP |
|||||||||||
|
to adjusted diluted (loss) income per common share, non-GAAP: |
|||||||||||
|
Diluted income (loss) per common share, GAAP: |
$ |
0.26 |
$ |
(0.08) |
$ |
0.13 |
$ |
(0.35) | |||
|
Adjustments: |
|||||||||||
|
Amortization expense |
0.11 | 0.09 | 0.33 | 0.25 | |||||||
|
Gain from sale of non-financial assets |
(0.41) |
-- |
(0.40) |
-- |
|||||||
|
Business development, integration, and severance expense |
0.04 | 0.16 | 0.15 | 0.20 | |||||||
|
Non-cash interest expense |
0.01 | 0.04 | 0.05 | 0.06 | |||||||
|
Corporate rebranding expense |
0.01 |
-- |
0.01 | 0.01 | |||||||
|
Tax effect of non-GAAP adjustments |
0.06 | (0.07) | (0.03) | (0.13) | |||||||
|
Effect of 25% pro forma tax rate |
(0.11) | (0.01) | (0.11) | 0.01 | |||||||
|
Adjusted diluted (loss) income per common share, |
|||||||||||
|
non-GAAP |
$ |
(0.03) |
$ |
0.13 |
$ |
0.13 |
$ |
0.05 | |||
|
|
|||||||||||
|
Reconciliation of diluted weighted-average common shares outstanding |
|||||||||||
|
GAAP to diluted weighted-average common shares outstanding, non-GAAP: |
|||||||||||
|
Diluted weighted-average common shares outstanding, GAAP: |
44,453 | 37,912 | 39,496 | 37,608 | |||||||
|
Adjustments: |
|||||||||||
|
Effect of dilutive stock options and awards |
(505) | 445 |
-- |
543 | |||||||
|
Effect of convertible senior notes |
(4,862) |
-- |
-- |
-- |
|||||||
|
Diluted weighted-average common shares outstanding, non-GAAP |
39,086 | 38,357 | 39,496 | 38,151 | |||||||
Page 9 of 9